+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antibody-Mediated Rejection - Market Insight, Epidemiology and Market Forecast 2030

  • ID: 5292794
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 132 pages
  • DelveInsight

FEATURED COMPANIES

  • CSL Behring
  • Hansa Biopharma
This ‘Antibody-Mediated Rejection (AMR) - Market Insights, Epidemiology, and Market Forecast - 2030’ report deliver an in-depth understanding of the AMR, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The AMR market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted AMR symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current AMR symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period:
2017-2030

AMR Disease Understanding and Treatment Algorithm

AMR Overview

Antibody-mediated rejection (AMR) is a major cause of late kidney transplant failure. Antibody-mediated rejection (AMR), also known as B-cell-mediated or humoral rejection, is a significant complication after kidney transplantation that carries a poor prognosis. Although fewer than 10% of kidney transplant patients experience AMR, as many as 30% of these patients experience graft loss as a consequence. Although AMR is mediated by antibodies against an allograft and results in histologic changes in allograft vasculature that differ from cellular rejection, it has not been recognized as a separate disease process until recently. With an improved understanding of the importance of the development of antibodies against allografts as well as complement activation, significant advances have occurred in the treatment of AMR.

Many unmet needs are associated with this disorder; there is no approved standard of care, subtype distinctions are not clearly defined, and increased therapy toxicity. Therefore, it becomes imperative that such needs are fulfilled to have an efficient and reliable method to treat this disease.

AMR Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the AMR market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The AMR market report gives a thorough understanding of AMR symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides AMR symptoms of treatment algorithms and treatment guidelines for AMR symptoms in the US, Europe, and Japan.

In concordance with these views, treatment protocols for AMR use permutations of a multiple-prong approach that include (1) the suppression of the T-cell dependent antibody response, (2) the removal of donor reactive antibody, (3) the blockade of the residual alloantibody, and (4) the depletion of naive and memory B-cells. Although all published protocols report a variable rate of success, a major weakness of all current protocols is the lack of effective anti-plasma cell agents.

AMR Epidemiology

The AMR symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total incident cases of AMR is increasing by 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted AMR symptoms epidemiology segmented as the Transplant incidence of AMR, and Antibody-Mediated Rejection cases. The report includes the incident scenario of AMR symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise AMR Epidemiology

The epidemiology segment also provides the AMR epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total incident cases of AMR associated in 7MM countries was 5,283 in 2020.

AMR Drug Chapters

The drug chapter segment of the AMR report encloses the detailed analysis of AMR early-stage (Phase-I, II, III) pipeline drugs. It also helps understand the AMR clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

AMR Emerging Drug

Clazakizumab: CSL Behring

Clazakizumab is a potent, monoclonal antibody that binds to and inhibits IL-6, an important driver of the inflammatory response that is known to play a key role in transplant rejection. While advances in transplantation techniques and therapies have markedly improved short-term success rates over the past 15-20 years, long-term graft survival remains one of the greatest challenges, with AMR recognized as the most common cause of long-term kidney allograft failure.

Imlifidase: Hansa Biopharma

Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically target IgG and inhibits IgG-mediated immune response. Using imlifidase is a novel approach to eliminate pathogenic IgG. It has a rapid onset of action, cleaving IgG-antibodies, and inhibiting their reactivity within hours after administration.

AMR Market Outlook

The AMR market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted AMR market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of AMR market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the AMR market in 7MM is expected to grow in the study period 2017-2030.

The primary aims of nearly all therapeutic approaches for AMR are removing circulating DSA and reducing DSA production. In this sense, the strongholds for contemporary treatment of AMR are represented by plasma exchange (PLEX) and IVIG, although neither of these has FDA approval. Over the last decade, the complement system has attracted increasing attention as an important contributor to AMR. The main goal of using complement inhibitors is to avoid the downstream damage to the allograft from DSA. Eculizumab is one such therapy that results in terminal complement blockade as a monoclonal antibody targeting C5.

Key Findings

This section includes a glimpse of the AMR market in 7MM. The market size of AMR in the seven major markets was USD 90.22 million in 2020.

The United States Market Outlook

This section provides the total AMR market size and market size by therapies in the United States.

The United States accounts for the largest market size of AMR in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total AMR market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total AMR market Size and market Size by therapies in Japan are also mentioned.

AMR Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers AMR market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

AMR Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase II and III stages. It also analyses AMR key players involved in developing targeted therapeutics.

Major players include CSL Behring, Hansa Biopharma, and Viela Bio.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for AMR emerging therapies.

Reimbursement Scenario in AMR

Approaching reimbursement, proactively, can have a positive impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

One US-based study estimated that the per-patient cost of AMR was USD 25,000 (2011 USD), based on the costs of biopsy, 3-day hospital stay, pulse steroids, IVIG (2 g/ kg), and rituximab (1 g). The same study also estimated a cost of USD 103,000 in the year of the event for patients who experienced graft loss due to AMR, the largest component of which was the cost associated with returning to dialysis. In 2011, Marfo and colleagues considered a similar treatment protocol based on costs associated with desensitization protocols in the US. The study assumed two high-dose IVIG infusions at 2 g/kg and a single dose of rituximab at 375 mg/m2 at a total cost per transplantation of USD 21,000. This cost was assumed for every transplantation conducted in sensitized patients rather than as an AMR treatment strategy, but the same procedure would be followed again in desensitized patients experiencing AMR. The authors noted that an additional USD 10,000 would be added to the total cost of desensitization in the case where plasmapheresis is indicated. A third US-based study estimated higher average costs of AMR events, with estimates ranging between USD 49,000 (based on biopsy, 2-day hospital stay, and treatment with IVIG plus rituximab) to USD 155,000 (based on 10 sessions of plasmapheresis, IVIG and 20 days in hospital; 2005-2006 USD).

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the AMR domain through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or AMR market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the AMR Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of AMR, explaining its causes, signs and symptoms, physiology, and currently available therapies
  • Comprehensive insight has been provided into the AMR epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for AMR is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the AMR market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global AMR market
Report Highlights
  • In the coming years, the AMR market is set to change due to the rising awareness of the disease, and the Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence AMR R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for AMR. The launch of emerging therapies will significantly impact the AMR market
  • the in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
AMR Report Insights
  • Patient Population
  • Therapeutic Approaches
  • AMR Pipeline Analysis
  • AMR Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
AMR Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
  • AMR Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
AMR Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the AMR Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the AMR total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings of the market across 7MM and which country will have the largest AMR market Size during the forecast period (2017-2030)?
  • At what CAGR, the AMR market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the AMR market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the AMR market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burdens, and unmet needs of the AMR?
  • What is the historical AMR patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of AMR in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about AMR?
  • Out of all 7MM countries, which country would have the largest prevalent population of AMR during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of AMR along with the approved therapy?
  • What are the current treatment guidelines for the treatment of AMR in the USA, Europe, and Japan?
  • What are the AMR marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of AMR?
  • How many therapies are developed by each company for the treatment of AMR?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of AMR?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the AMR therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for AMR and its status?
  • What are the key designations that have been granted for the emerging therapies for AMR?
  • What are the global historical and forecasted market of AMR?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the AMR market
  • To understand the future market competition in the AMR market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for AMR in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the AMR market
  • To understand the future market competition in the AMR market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • CSL Behring
  • Hansa Biopharma
1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 Antibody-Mediated Rejection (AMR): Market Overview at a Glance
5.1 Total Market Share (%) Distribution of Antibody-Mediated Rejection (AMR) in 2017
5.2 Total Market Share (%) Distribution of Antibody-Mediated Rejection (AMR) in 2030

6 Antibody-Mediated Rejection (AMR): Market Overview at a Glance
6.1 Introduction
6.2 Pathogenesis
6.3 Types of ABR
6.4 Risk Factors
6.5 Clinical features
6.6 Diagnosis

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Total cases of Antibody-Mediated Rejection (AMR) in 7MM
7.4 United States
7.4.1 Transplant Incidence cases in the United States
7.4.2 Antibody-Mediated Rejection Cases in the United States
7.5 EU5 Countries
7.6 Germany
7.6.1 Transplant Incidence cases in Germany
7.6.2 Antibody-Mediated Rejection Cases in Germany
7.7 France
7.7.1 Transplant Incidence cases in France
7.7.2 Antibody-Mediated Rejection Cases in France
7.8 Italy
7.8.1 Transplant Incidence cases in Italy
7.8.2 Antibody-Mediated Rejection Cases in Italy
7.9 Spain
7.9.1 Transplant Incidence cases in Spain
7.9.2 Antibody-Mediated Rejection Cases in Spain
7.10. UK
7.10.1 Transplant Incidence cases in the United Kingdom
7.10.2 Antibody-Mediated Rejection Cases in the United Kingdom
7.11 Japan
7.11.1 Transplant Incidence cases in Japan
7.11.2 Antibody-Mediated Rejection Cases in Japan

8 Treatment of Antibody-Mediated Rejection (AMR)

9 Unmet Needs

10 Emerging Therapies
10.1 Key Cross Competition
10.1.1 Other promising therapies
10.2 Clazakizumab: CSL Behring
10.2.1 Drug Description
10.2.2 Other Development Activities
10.2.3 Clinical Development
10.2.4 Safety and Efficacy
10.2.5 Product Profile
10.3 Imlifidase: Hansa Biopharma
10.3.1 Drug Description
10.3.2 Other Development Activities
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile
10.4 VIB4920: Viela Bio
10.4.1 Drug Description
10.4.2 Clinical Development
10.4.3 Safety and Efficacy
10.4.4 Product Profile
10.5 Inebilizumab-cdon: Viela Bio
10.5.1 Drug Description
10.5.2 Clinical Development
10.5.3 Product Profile
10.6 Daratumumab: Janssen Biotech
10.6.1 Drug Description
10.6.2 Other Development Activities
10.6.3 Clinical Development
10.6.4 Product Profile

11 Antibody-Mediated Rejection (AMR): 7 Major Market Analysis
11.1 Key Findings
11.2 Market Size of Antibody-Mediated Rejection (AMR) in 7MM

12 Seven Major Market Outlook

13 United States Market Size
13.1 Total Market Size of Antibody-Mediated Rejection (AMR) in the United States
13.2 Total Market Size of Antibody-Mediated Rejection (AMR) by Therapies in the United States
13.3 Germany
13.3.1 Total market size of Antibody-Mediated Rejection (AMR) in Germany
13.3.2 Total market size of Antibody-Mediated Rejection (AMR) by Therapies in Germany
13.4 France
13.4.1 Total market size of Antibody-Mediated Rejection (AMR) in France
13.4.2 Total Market size of Antibody-Mediated Rejection (AMR) by Therapies in France
13.5 Italy
13.5.1 Total market size of Antibody-Mediated Rejection (AMR) in Italy
13.5.2 Total Market size of Antibody-Mediated Rejection (AMR) by Therapies in Italy
13.6 Spain
13.6.1 Total Market Size of Antibody-Mediated Rejection (AMR) in Spain
13.6.2 Total market size of Antibody-Mediated Rejection (AMR) by Therapies in Spain
13.7 United Kingdom
13.7.1 Total market size of Antibody-Mediated Rejection (AMR) in the United Kingdom
13.7.2 Total market size of Antibody-Mediated Rejection (AMR) by Therapies in the UK
13.8 Japan
13.8.1 Total market size of Antibody-Mediated Rejection (AMR) in Japan
13.8.2 Total market size of Antibody-Mediated Rejection (AMR) by Therapies in Japan

14 Market Drivers

15 Market Barriers

16 SWOT Analysis

17 Market Access

18 Case Study
18.1 Antibody-mediated Rejection in Heart Transplantation: Case Presentation with a Review of Current International Guidelines
18.2 Eculizumab for the Treatment of Severe Antibody-mediated Rejection: A Case Report
18.3 Antibody-mediated rejection with detection of de novo donor-specific anti-human leukocyte antigen Class II antibodies 3 years after heart transplantation: A Case Report
18.4 Bortezomib against Refractory Antibody-mediated Rejection after ABO-Incompatible Living-donor Liver Transplantation: Dramatic Effect in Acute Phase?

19 KOL Views

20 Bibliography

21 Appendix
21.1 Report Methodology

22 Publisher Capabilities

23 Disclaimer

24 About the Publisher

List of Tables
Table 1: Banff diagnostic categories
Table 2: Antibody-mediated rejection criteria
Table 3: Total cases of Antibody-Mediated Rejection (AMR) in 7MM (2017-2030)
Table 4: Transplant Incidence cases in the United States (2017-2030)
Table 5: Antibody-Mediated Rejection Cases in the US (2017-2030)
Table 6: Transplant Incidence cases in Germany (2017-2030)
Table 7: Antibody-Mediated Rejection Cases in Germany (2017-2030)
Table 8: Transplant Incidence cases in France (2017-2030)
Table 9: Antibody-Mediated Rejection Cases in France (2017-2030)
Table 10: Transplant Incidence cases in Italy (2017-2030)
Table 11: Antibody-Mediated Rejection Cases in Italy (2017-2030)
Table 12: Transplant Incidence cases in Spain (2017-2030)
Table 13: Antibody-Mediated Rejection Cases in Spain (2017-2030)
Table 14: Transplant Incidence cases in the United Kingdom (2017-2030)
Table 15: Antibody-Mediated Rejection Cases in the UK (2017-2030)
Table 16: Transplant Incidence cases in Japan (2017-2030)
Table 17: Antibody-Mediated Rejection Cases in Japan (2017-2030)
Table 18: Clazakizumab, Clinical Trial Description, 2020
Table 19: Imlifidase, Clinical Trial Description, 2020
Table 20: VIB4920, Clinical Trial Description, 2020
Table 21: Inebilizumab, Clinical Trial Description, 2020
Table 22: Daratumumab, Clinical Trial Description, 2020
Table 23: Market Size of Antibody-Mediated Rejection (AMR) in 7MM in USD Million (2017-2030)
Table 24: US Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)
Table 25: US Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)
Table 26: Market Size of Antibody-Mediated Rejection (AMR) in Germany, USD Millions (2017-2030)
Table 27: Germany Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)
Table 28: Market Size of Antibody-Mediated Rejection (AMR) associated in France, USD Millions (2017-2030)
Table 29: France Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)
Table 30: Market Size of Antibody-Mediated Rejection (AMR) in Italy, USD Millions (2017-2030)
Table 31: Italy Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)
Table 32: Market Size of Antibody-Mediated Rejection (AMR) in Spain, USD Millions (2017-2030)
Table 33: Spain Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)
Table 34: Market Size of Antibody-Mediated Rejection (AMR) in the UK, USD Millions (2017-2030)
Table 35: UK Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)
Table 36: Market Size of Antibody-Mediated Rejection (AMR) in Japan, USD Millions (2017-2030)
Table 37: Japan Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)

List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Activation of the Classical Complement Pathway in AMR in Renal Transplant Recipients
Figure 3: Complement Activation Pathway
Figure 4: Total Cases of Antibody-Mediated Rejection (AMR) in 7MM (2017-2030)
Figure 5: Transplant incidence Cases in the United States (2017-2030)
Figure 6: Antibody-Mediated Rejection Cases in the US (2017-2030)
Figure 7: Transplant incidence Cases in Germany (2017-2030)
Figure 8: Antibody-Mediated Rejection Cases in Germany (2017-2030)
Figure 9: Transplant incidence Cases in France (2017-2030)
Figure 10: Antibody-Mediated Rejection Cases in France (2017-2030)
Figure 11: Transplant incidence Cases in Italy (2017-2030)
Figure 12: Antibody-Mediated Rejection Cases in Italy (2017-2030)
Figure 13: Transplant incidence Cases in Spain (2017-2030)
Figure 14: Antibody-Mediated Rejection Cases in Spain (2017-2030)
Figure 15: Transplant incidence Cases in the United Kingdom (2017-2030)
Figure 16: Antibody-Mediated Rejection Cases in the UK (2017-2030)
Figure 17: Transplant incidence Cases in Japan (2017-2030)
Figure 18: Antibody-Mediated Rejection Cases in Japan (2017-2030)
Figure 19: Suggested Algorithm For Management of AMR
Figure 20: Unmet Needs
Figure 21: Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)
Figure 22: Market Size of Antibody-Mediated Rejection (AMR) in the US, USD Millions (2017-2030)
Figure 23: Market Size of Antibody-Mediated Rejection (AMR) in the US by therapies, USD Millions (2017-2030)
Figure 24: Market Size of Antibody-Mediated Rejection (AMR) in Germany, USD Millions (2017-2030)
Figure 25: Market Size of Antibody-Mediated Rejection (AMR) in Germany by therapies, USD Millions (2017-2030)
Figure 26: Market Size of Antibody-Mediated Rejection (AMR) in France, USD Millions (2017-2030)
Figure 27: Market Size of Antibody-Mediated Rejection (AMR) in France by therapies, USD Millions (2017-2030)
Figure 28: Market Size of Antibody-Mediated Rejection (AMR) in Italy, USD Millions (2017-2030)
Figure 29: Market Size of Antibody-Mediated Rejection (AMR) in Italy by therapies, USD Millions (2017-2030)
Figure 30: Market Size of Antibody-Mediated Rejection (AMR) in Spain, USD Millions (2017-2030)
Figure 31: Market Size of Antibody-Mediated Rejection (AMR) in Spain by therapies, USD Millions (2017-2030)
Figure 32: Market Size of Antibody-Mediated Rejection (AMR) in the UK, USD Millions (2017-2030)
Figure 33: Market Size of Antibody-Mediated Rejection (AMR) in the UK by therapies, USD Millions (2017-2030)
Figure 34: Market Size of Antibody-Mediated Rejection (AMR) in Japan, USD Millions (2017-2030)
Figure 35: Market Size of Antibody-Mediated Rejection (AMR) in Japan by therapies, USD Millions (2017-2030)
Figure 36: Market Drivers
Figure 37: Market Barriers
Note: Product cover images may vary from those shown
  • Hansa Biopharma
  • CSL Behring
Note: Product cover images may vary from those shown
Adroll
adroll